Press Releases

Press Releases

Date Title
July 30, 2020
Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4 + and CD8 + T cell responses in 100% of treated patients CAMBRIDGE, Mass.
July 23, 2020
Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT Filed IND application for GEN-011 and is working with the FDA to provide additional information Private Placement with Leading Life Science Investment Funds Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass.
July 22, 2020
CAMBRIDGE, Mass. , July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement led by an undisclosed leading U.S.
July 20, 2020
CAMBRIDGE, Mass. , July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy,
July 16, 2020
CAMBRIDGE, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second quarter 2020 financial results and corporate update conference call and live audio webcast
June 22, 2020
Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy Inhibigens alter the tumor microenvironment and drive tumor hyperprogression Inhibigens abolish both global and tumor antigen-specific T cell activity CAMBRIDGE, Mass.
June 15, 2020
Preliminary clinical data expected mid-2021 CAMBRIDGE, Mass. , June 15, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application
May 29, 2020
Data show immune responses occur rapidly after only two vaccinations and  can be sustained for more than one year Part B is exploring the vaccine's ability to reduce tumor size beyond the standard-of-care therapy alone CAMBRIDGE, Mass. , May 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
May 19, 2020
CAMBRIDGE, Mass. , May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co.,
May 13, 2020
Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up ATLAS™-identified neoantigens generate broad, sustained T cell responses starting after only 4 weeks and lasting for up to 6 months after the last vaccination CAMBRIDGE, Mass.
May 12, 2020
GEN-011 IND filing by end of Q2 with preliminary clinical data expected in 1H 2021 CAMBRIDGE, Mass. , May 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr.
May 11, 2020
Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT CAMBRIDGE, Mass. , May 11, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and
May 5, 2020
Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT CAMBRIDGE, Mass. , May 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and
April 30, 2020
Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12 th Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Genocea
April 23, 2020
Virtual KOL symposium scheduled for May 12th to review GEN-011 – neoantigen T cell therapy – and the evolving T cell therapy landscape CAMBRIDGE, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen
April 8, 2020
CAMBRIDGE, Mass. , April 08, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the 19th
February 26, 2020
CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the Cowen
February 20, 2020
CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the SVB
February 13, 2020
ATLAS TM identifies Inhibigens tm that can undermine immunotherapy Dosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trial Progressed GEN-011 neoantigen cell therapy - IND filing expected in Q2 2020 Appointed Dr. Gisela Schwab to Genocea’s Board of Directors Conference call
February 6, 2020
CAMBRIDGE, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019 financial results and corporate update conference call and live audio webcast